Sheryl Conley Acquires Shares of ANIK
Sheryl Conley purchased 10,402 shares of ANIK on June 18, 2026.
Key Points
- Sheryl Conley bought 10,402 shares of ANIK on June 18, 2026, which was not a planned transaction.
- Shares of ANIK traded near $14.20 on Wednesday, with significant institutional activity surrounding the stock.
- Barrington Research maintained a 'buy' rating on ANIK with a price target of $17.00 as of February 27, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Sheryl Conley recently made a move in the stock market by purchasing 10,402 shares of ANIK on June 18, 2026. This insider transaction was not planned in advance, and the details of the purchase price and total value were not disclosed.
Insider Buying and Selling at Anika Therapeutics, Inc.
Sheryl Conley wasn't the only insider buying ANIK shares. On the same day, several other insiders, including Richard Stephen, Gary Fischetti, Joseph Capper, John Henneman III, and Stephen Griffin, also acquired 10,402 shares each. Stephen Griffin, who is the President and CEO, had previously purchased 12,840 shares on June 3, 2026.
Other Institutional Activity in ANIK
Several institutional investors have been active with ANIK shares. BlackRock, Inc. reduced its holdings by 59,644 shares, leaving it with 1,594,893 shares worth about $23.13 million. Morgan Stanley, on the other hand, increased its position by 99,836 shares, now owning 872,066 shares valued at approximately $12.64 million. Vanguard Capital Management LLC opened a new position with 605,777 shares valued at $8.78 million. Meanwhile, Boothbay Fund Management, LLC slightly trimmed its stake by 5,004 shares, maintaining 529,503 shares worth about $7.68 million.
Anika Therapeutics, Inc. Stock Down 32.7%
Shares of ANIK traded near $14.20 on Wednesday. The stock has seen various institutional activities, reflecting broader market interest. The current trading environment and insider activities might suggest differing views on the company’s future prospects.
$ANIK stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On February 27, 2026, Barrington Research maintained its 'buy' rating on ANIK, setting a price target of $17.00. This consistent 'buy' stance from Barrington Research over several months indicates confidence in the company's potential.
Bottom Line
Sheryl Conley's purchase of ANIK shares, along with similar moves by other insiders, highlights notable activity around the stock. Investors keep an eye on such insider transactions as they can sometimes offer insights into the company’s prospects. However, these transactions are part of regular reporting and may not reflect current positions or future expectations.
Get Anika Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ANIK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.